乳房切除与乳房再造后慢性疼痛患病率及特征的系统综述与荟萃分析
荟萃分析显示,乳房切除后慢性疼痛平均患病率为41.79%(CI: 33.08, 50.49),即刻异体乳房再造后为49.47%(CI: 32.95, 66.00),延迟自体乳房再造后为42.81%(CI: -3.55, 89.17)。作者结论为慢性疼痛常见,需采用经过验证的乳腺癌特异性疼痛评估工具进一步研究再造时机与类型的影响。
要点
- 乳房切除后慢性疼痛平均患病率为41.79%(CI: 33.08, 50.49)。
- 即刻异体乳房再造后慢性疼痛患病率为49.47%(CI: 32.95, 66.00)。
- 延迟自体乳房再造后慢性疼痛患病率为42.81%(CI: -3.55, 89.17)。
核心结论
- 乳房切除与乳房再造后慢性疼痛普遍存在,需采用经过验证的乳腺癌特异性疼痛评估工具进一步研究再造时机与类型对慢性疼痛的影响。
研究设计与样本
- 纳入标准要求术后随访至少三个月,疼痛位于乳房、同侧胸壁、腋窝、手臂或供区。
- 荟萃分析采用随机效应模型,报告95%置信区间(CI)。
主要发现
- 85%的研究报告了至少一项次要结局。
- 乳房切除后慢性疼痛平均患病率为41.79%(CI: 33.08, 50.49)。
- 即刻异体乳房再造后慢性疼痛平均患病率为49.47%(CI: 32.95, 66.00),延迟自体乳房再造后为42.81%(CI: -3.55, 89.17)。
关键数值与推荐
- 慢性疼痛患病率:乳房切除后41.79%(CI: 33.08, 50.49);即刻异体乳房再造后49.47%(CI: 32.95, 66.00);延迟自体乳房再造后42.81%(CI: -3.55, 89.17)。
临床怎么用
- 临床应关注乳房切除及乳房再造术后慢性疼痛的评估与管理。
- 建议使用经过验证的乳腺癌特异性疼痛评估工具进行系统评估。
- 再造时机与类型对慢性疼痛的影响尚需进一步研究明确。
局限性
- 延迟自体乳房再造的患病率置信区间较宽(CI: -3.55, 89.17),提示估计不确定性较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to investigate chronic pain in mastectomy alone, as well as alloplastic reconstruction and autologous reconstruction following mastectomy. Primary outcome included comparing overall chronic pain prevalence between these breast procedures. Secondary outcomes included describing 1) characteristics and location of chronic pain and 2) chronic pain intensity. METHODS: MEDLINE, Embase, and Web of Science were searched on December 9, 2024 with no restriction on the date of publication. Titles, abstracts, and full texts screening and data extraction was conducted independently and in duplicate. Inclusion criteria required: 1) mastectomy with or without breast reconstruction for breast cancer or risk reduction, (2) minimum three-month post-operative follow-up, (3) pain in the breast, ipsilateral chest wall, axilla, arm, or donor site after breast surgery. Meta-analyses were carried out using a random-effects model with 95% confidence interval (CI). RESULTS: Ninety-one studies with 26,132 patients with breast cancer were included in this systematic review. Sixteen different pain scales were used to describe chronic pain. Overall, 85% of studies reported at least one secondary outcome. Fifty-two studies were pooled for meta-analyses. Mean chronic pain prevalence following mastectomy was 41.79% (CI: 33.08, 50.49). Mean chronic pain prevalence was 49.47% (CI: 32.95, 66.00) and 42.81% (CI: -3.55, 89.17) following immediate alloplastic reconstruction and delayed autologous reconstruction, respectively. CONCLUSION: Chronic pain following mastectomy and reconstruction is prevalent. Therefore, studies that better characterize how timing and type of breast reconstruction affect chronic pain, using validated breast cancer specific pain assessment tools, are warranted.
引用
- Churchill IF, O'Connor A, Land SA, et al. Prevalence and characteristics of chronic pain following mastectomy and breast reconstruction: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2025. PMID: 41047282. doi:10.1016/j.bjps.2025.08.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。